Michael L. Maitland
Inova Health System · 213 works · 8,796 citations · h-index 37
Top works
- Host Defense Mechanisms Triggered by Microbial Lipoproteins Through Toll-Like Receptors
- CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
- Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer
- Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1α-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer
- Mycobacterial infection of macrophages results in membrane-permeable phagosomes
- Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
- Cancer pharmacogenomics: strategies and challenges
- CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema
- Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway
- Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data
- RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox—Point
- Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population Genetics
- Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
- Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
- Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology
- Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets